Allen Baharaff | President & Chief Executive Officer |
Yohai Stenzler | Chief Financial Officer |
Dr. Liat Hayardeny | Chief Scientific Officer |
Steve Seedhouse | Raymond James |
Kristen Kluska | Cantor Fitzgerald |
Ed Arce | H.C. Wainwright |
Good day, and welcome to the Galmed Conference Call to discuss financial results for the third quarter of 2020. Today's conference is being recorded.
Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated time lines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events. These statements are based on beliefs and expectations of management as of today, and actual results, trends, time lines and projections relating to our financial position and projected development programs and pipeline could differ materially. In particular, there is a significant uncertainty about the duration and severity of the COVID-19 pandemic and its impact on Galmed's business and operations.